Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

Abdel-Wahab, Reham ; Varadhachary, Gauri R ; Bhosale, Priya R ; Wang, Xuemei ; Fogelman, David R ; Shroff, Rachna T ; Overman, Michael J ; Wolff, Robert A ; Javle, Milind

Journal of hematology and oncology, 2018-05, Vol.11 (1), p.71-9, Article 71 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível